secwatch.observer — SEC 8-K summary
======================================

Issuer:     Notable Labs, Ltd. (—)
CIK:        0001603207
Form:       8-K
Filed at:   2024-09-19T23:59:59+00:00
Accession:  0001493152-24-037122
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.05
LLM model:  deepseek-v4-flash:cloud@v2

Notable Labs restructures: pauses Phase 2 Volasertib study, cuts 65% of workforce
--------------------------------------------------------------------------------

- Board approved streamlined operating plan to explore strategic alternatives for maximizing shareholder value.
- Phase 2 study of Volasertib in relapsed/refractory AML paused immediately.
- Workforce and outside consultants reduced by ~65%; expected completion by September 24, 2024.
- Anticipates ~$0.1 million in charges for termination benefits, recognized in Q3 and Q4 2024.
- Kaile A. Zagger appointed as Chief Restructuring Officer and Interim CEO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1603207/000149315224037122/0001493152-24-037122-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1603207/000149315224037122/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-037122

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer